Buechi introduces industrial rotary evaporator

Published: 28-Apr-2010
Manufacturing

Swiss firm upgrades Rotovapor R-220 with the latest technology and focuses on safety and easy handling

Buechi introduces industrial rotary evaporator
Buechi Labortechnik of Switzerland has upgraded the 20-litre Rotavapor R-220 after 10 years on the market.

The new Rotavapor R-220 SE (Second Edition) focuses on safety and easy handling and incorporates the latest technology.

The patented flask fixation and the EasyClamp enable a fast and safe installation of the glass parts and the clearly arranged design of the control panels reduces the risk of operating errors, the company says.

An optional shield also protects the instrument in rough environments.

Further new features include a USB module that enables the process data to be saved on a memory stick and a level sensor that monitors the receiving flask so that the instrument is stopped as soon as the flask is full. In addition, USB and RS485 interfaces provide for the control of system components such as a vacuum pump or recirculating chiller.

The large and bright 6in display provides all information about the distillation process. The large high-contrast digits indicating the bath-, vapour- and cooling temperature, as well as the rotation speed, are clearly visible, also from a distance.

An integrated vacuum controller guarantees reproducible and stable conditions and the wide choice of 7 different glass configurations enable the instrument to be adapted for almost any application.

See more

You may also like

Manufacturing
Xelia and Hisun sign strategic global multiple-API partnership

Xelia and Hisun sign strategic global multiple-API partnership

Read more
Long-standing joint venture partners expand collaboration, moving beyond anti-infective APIs into diversified therapeutic areas, including cardiovascular and oncology

Trending Articles

  1. Sterling Pharma Solutions doubles ADC manufacturing capacity at Deeside with new GMP suite The multi-million-pound expansion adds a 1400 sqft Grade C cleanroom, OEB5 containment handling and a 3400 sqft analytical laboratory — extending Sterling's bioconjugation capability from development through to Phase III and commercial scale
  2. FDA inspection readiness: Preparing for surveillance and pre-approval inspections Preparing pharma and biotech teams for continuous FDA inspection readiness, mock inspections and proactive regulatory risk management
  3. Hovione to install first ConsiGma CDC Flex continuous tableting line in US The CDMO is investing $35m in a next-generation continuous tableting line at its 89 Twin Rivers facility in New Jersey, creating an integrated US pathway from spray-dried amorphous solid dispersions to commercial tablet production
  4. SCHOTT Pharma makes decarbonisation measurable Validated carbon footprint tool supports informed Scope 3 reduction decisions for pharmaceutical packaging
  5. FDA Form 483 explained: responding to findings and managing regulatory risk Explore what a Form FDA 483 means, how to respond within 15 business days, assess patient risk, address observations and understand how FDA evaluates responses and inspection outcomes

You may also like

Manufacturing
Xelia and Hisun sign strategic global multiple-API partnership

Xelia and Hisun sign strategic global multiple-API partnership

Long-standing joint venture partners expand collaboration, moving beyond anti-infective APIs into diversified therapeutic areas, including cardiovascular and oncology
Manufacturing
Patented device reinvents Solid Phase Extraction

Patented device reinvents Solid Phase Extraction

Biotech Fluidics announce SPEedy - a device that provides an effortless way to perform Solid Phase Extraction (SPE) sample preparation procedures without need of an external vacuum and compatible with any adsorption chemistry or eluent composition
Manufacturing
Orano Med inaugurates Europe's first industrial-scale lead-212 radioligand therapy facility

Orano Med inaugurates Europe's first industrial-scale lead-212 radioligand therapy facility

The €29m ATLab site will target up to 10,000 doses annually and its two-hour proximity to major European airports meets the critical 24-hour production-to-administration window imposed by lead-212's 10.6-hour half-life
Manufacturing
Lonza advances aseptic spray drying for high-dose biologics

Lonza advances aseptic spray drying for high-dose biologics

This new technology platform addresses stability, concentration, and delivery challenges in biologics, including new modalities
Manufacturing
Catalent launches ten-month gene-to-drug substance programme for complex biologics

Catalent launches ten-month gene-to-drug substance programme for complex biologics

The accelerated pathway extends the CDMO's Rapid Antibody framework to bispecifics and next-generation formats — targeting master cell bank release by month seven and bulk drug substance lot release by month ten
Design & Build
Sterling Pharma Solutions doubles ADC manufacturing capacity at Deeside with new GMP suite

Sterling Pharma Solutions doubles ADC manufacturing capacity at Deeside with new GMP suite

The multi-million-pound expansion adds a 1400 sqft Grade C cleanroom, OEB5 containment handling and a 3400 sqft analytical laboratory — extending Sterling's bioconjugation capability from development through to Phase III and commercial scale
Manufacturing
Piramal Pharma Solutions and NP2 to complete cyclophosphamide development phase next month

Piramal Pharma Solutions and NP2 to complete cyclophosphamide development phase next month

Piramal Pharma Solutions (“PPS”), a leading global Contract Development and Manufacturing Organisation (CDMO) and part of Piramal Pharma Ltd. (“PPL”) (NSE: PPLPHARMA | BSE: 543635), and its partner NP2, a nonprofit generic drug manufacturer, today announced their plans to finish the drug development phase of the generic cancer drug cyclophosphamide in October
Subscribe now